<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ETF Trends &#187; FBT</title>
	<atom:link href="http://www.etftrends.com/tag/fbt/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.etftrends.com</link>
	<description>Setting the Pace for Exchange Traded Funds</description>
	<lastBuildDate>Sun, 12 Feb 2012 11:00:32 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Biotech ETFs Break Out</title>
		<link>http://www.etftrends.com/2012/01/biotech-etfs-break-out/</link>
		<comments>http://www.etftrends.com/2012/01/biotech-etfs-break-out/#comments</comments>
		<pubDate>Thu, 19 Jan 2012 14:45:51 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=74303</guid>
		<description><![CDATA[The rally in biotechnology exchange traded funds is going vertical in early 2012 with the sector&#8217;s largest ETF posting a gain of 20% over the past three months.
The $1.5 billion iShares Nasdaq Biotechnology Index Fund (IBB) is breaking out to new all-time highs. The ETF is up 9.6% year to date, compared with a 4.1% [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/01/biotech-etfs-break-out/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs: Orexigen Hit By Regulatory Hammer</title>
		<link>http://www.etftrends.com/2011/06/biotech-etfs-orexigen-hit-by-regulatory-hammer/</link>
		<comments>http://www.etftrends.com/2011/06/biotech-etfs-orexigen-hit-by-regulatory-hammer/#comments</comments>
		<pubDate>Fri, 03 Jun 2011 19:47:41 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPH]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=55162</guid>
		<description><![CDATA[Biotech sector and related exchange traded funds (ETFs) trade lower as one drug maker garners notoriety after regulatory hurdles puts a hold on the advancement of an anticipated diet pill.

iShares Nasdaq Biotechnology (NYSEArca: IBB) is down 0.83%.
First Trust Amex Biotech Index Fund (NYSEAca: FBT) is down 0.74%.
iShares Dow Jones U.S. Pharmaceutical Index Fund (NYSEArca: IHE) [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/06/biotech-etfs-orexigen-hit-by-regulatory-hammer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Teva, Cephalon Boost Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/#comments</comments>
		<pubDate>Mon, 02 May 2011 15:45:58 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=52575</guid>
		<description><![CDATA[Biotechnology exchange traded funds (ETFs) rallied to open the week after Teva Pharmaceutical (NasdaqGS: TEVA) said it’s buying Cephalon (NasdaqGS: CEPH) for $6.8 billion in a blockbuster sector deal.
The combined company would represent about $7 billion in annual sales. Shares of Teva and Cephalon were both up more than 3% in recent trading.
&#8220;This is transforming [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ETFs And A Global Approach Help Investors Access Biotech</title>
		<link>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/</link>
		<comments>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/#comments</comments>
		<pubDate>Fri, 11 Mar 2011 09:00:37 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=47499</guid>
		<description><![CDATA[Investing in biotech stocks and companies is so much like gambling, the risk is sometimes not worth it. Why not mitigate the risk and invest in an exchange traded fund (ETF) instead, which will give investors exposure to several companies at once.[Dissipate The Risk In Biotechnology With ETFs.]
According to MinyanVille, the process of New Drug [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 Biotechnology ETFs to Play Innovation</title>
		<link>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/</link>
		<comments>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/#comments</comments>
		<pubDate>Tue, 22 Feb 2011 22:00:10 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[HOLDRs]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46796</guid>
		<description><![CDATA[While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector.
Currently, the biotech industry is full of fast-growing and very profitable companies; however, [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 ETFs That Could Move on Obama&#8217;s Budget</title>
		<link>http://www.etftrends.com/2011/02/5-etfs-that-could-move-obamas-budget/</link>
		<comments>http://www.etftrends.com/2011/02/5-etfs-that-could-move-obamas-budget/#comments</comments>
		<pubDate>Mon, 14 Feb 2011 20:00:26 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Socially Responsible ETFs]]></category>
		<category><![CDATA[Aerospace & Defense]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Commodity ETFs]]></category>
		<category><![CDATA[Energy]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[GII]]></category>
		<category><![CDATA[Green ETFs]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[Infrastructure]]></category>
		<category><![CDATA[ITA]]></category>
		<category><![CDATA[Nuclear Energy]]></category>
		<category><![CDATA[Oil & Gas Exploration]]></category>
		<category><![CDATA[PKN]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XOP]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46448</guid>
		<description><![CDATA[President Obama is out with a new budget. If it goes through, the impact could be ugly for some exchange traded funds (ETFs) and lovely for others.
The federal budget as Obama envisions it stands at $3.7 trillion for 2012, which a chunk of it going to Medicare, Medicaid and Social Security. The rest of the [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/5-etfs-that-could-move-obamas-budget/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sector ETFs to Play the State of the Union Address</title>
		<link>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/</link>
		<comments>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/#comments</comments>
		<pubDate>Wed, 26 Jan 2011 20:00:06 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Socially Responsible ETFs]]></category>
		<category><![CDATA[Aerospace & Defense]]></category>
		<category><![CDATA[Alternative Energy]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Clean Energy]]></category>
		<category><![CDATA[Energy]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[FXH]]></category>
		<category><![CDATA[GEX]]></category>
		<category><![CDATA[Green ETFs]]></category>
		<category><![CDATA[GRID]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHF]]></category>
		<category><![CDATA[Infrastructure]]></category>
		<category><![CDATA[ITA]]></category>
		<category><![CDATA[IYW]]></category>
		<category><![CDATA[NASI]]></category>
		<category><![CDATA[PBW]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PJP]]></category>
		<category><![CDATA[PPA]]></category>
		<category><![CDATA[QQEW]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>
		<category><![CDATA[XLK]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=45357</guid>
		<description><![CDATA[In his State of the Union address Tuesday, President Barack Obama touched upon the major problems that have crippled our nation and offered an essential directive to invest in our future. If Obama&#8217;s proposals become actualities, something that&#8217;s not necessarily a certainty, then the exchange traded funds (ETFs) below could make moves.
President Obama stressed the [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dissipate the Risk In Biotechnology With ETFs</title>
		<link>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/</link>
		<comments>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/#comments</comments>
		<pubDate>Tue, 18 Jan 2011 22:00:17 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BIB]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[BIS]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=44690</guid>
		<description><![CDATA[The biotechnology sector offers investors the opportunity to bet big and win big, but the potential downside can make a huge dent in your wallet. Perhaps a biotech exchange traded fund (ETF) is more to your liking?
The largest and most liquid broad-based biotech sector iShares Nasdaq Biotechnology (NASDAQ: IBB), which reflects the performance of the [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Health Care ETFs May Be In the Clear</title>
		<link>http://www.etftrends.com/2010/11/why-health-care-etfs-may-be-in-the-clear/</link>
		<comments>http://www.etftrends.com/2010/11/why-health-care-etfs-may-be-in-the-clear/#comments</comments>
		<pubDate>Wed, 10 Nov 2010 19:00:49 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHF]]></category>
		<category><![CDATA[IXJ]]></category>
		<category><![CDATA[IYH]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PJP]]></category>
		<category><![CDATA[PTH]]></category>
		<category><![CDATA[RXD]]></category>
		<category><![CDATA[RXL]]></category>
		<category><![CDATA[RYH]]></category>
		<category><![CDATA[VHT]]></category>
		<category><![CDATA[XBI]]></category>
		<category><![CDATA[XLV]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=40871</guid>
		<description><![CDATA[After the Democrats lost some seats in the mid-term elections, you might be wondering whether health care revenue and exchange traded funds (ETFs) will be affected by the shift. Some don&#8217;t believe there&#8217;s anything to worry about for a while.
First, with most corporations backing major Congressional players, it is almost certain that the medical industry [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/11/why-health-care-etfs-may-be-in-the-clear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs May Soon Face Challenges</title>
		<link>http://www.etftrends.com/2010/11/biotech-etfs-may-soon-face-challenges/</link>
		<comments>http://www.etftrends.com/2010/11/biotech-etfs-may-soon-face-challenges/#comments</comments>
		<pubDate>Sat, 06 Nov 2010 20:00:26 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=40680</guid>
		<description><![CDATA[The Republican takeover of the House this week could have a negative impact on biotechnology exchange traded funds (ETFs).
Kenneth Chang for The New York Times reports that research and development at nonmilitary agencies — including those that sponsor science and health research — would fall 12.3 %, to $57.8 billion, down from President Obama’s requested [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/11/biotech-etfs-may-soon-face-challenges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Readying to Deliver the Goods</title>
		<link>http://www.etftrends.com/2010/11/biotech-etfs-readying-deliver-goods/</link>
		<comments>http://www.etftrends.com/2010/11/biotech-etfs-readying-deliver-goods/#comments</comments>
		<pubDate>Tue, 02 Nov 2010 20:00:53 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BIB]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=40365</guid>
		<description><![CDATA[Biotechnology exchange traded funds (ETFs) could be poised to deliver the goods as an aging population and demand for new treatments stokes growth in the sector.
A slew of factors are driving the sector these days, explains PR.com. They include:

Increasing demand for biotechnology drugs with enhanced efficiency, safety and popularity.
Revision of regulations and standards in favor [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/11/biotech-etfs-readying-deliver-goods/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 Things That Drive Biotech ETFs</title>
		<link>http://www.etftrends.com/2010/10/5-things-drive-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2010/10/5-things-drive-biotech-etfs/#comments</comments>
		<pubDate>Thu, 21 Oct 2010 22:00:55 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BIB]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=39693</guid>
		<description><![CDATA[The biotechnology sector is a unique one because many of the companies that compose it are not yet profitable. Here&#8217;s what drives the sector and exchange traded funds (ETFs) that let you play it.
Kashif Javed for Forex Trading Analysis reports that the biotech sector is driven by and dependent on several key things:

Mergers and acquisitions: [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/10/5-things-drive-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs:The Better Way to Play</title>
		<link>http://www.etftrends.com/2010/10/biotech-etfsbetter-way-play/</link>
		<comments>http://www.etftrends.com/2010/10/biotech-etfsbetter-way-play/#comments</comments>
		<pubDate>Mon, 11 Oct 2010 13:00:22 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=38873</guid>
		<description><![CDATA[As cash-strapped biotech companies see their cash reserves dwindle, it  has forced a number of companies to close up shop. The struggles faced in the sector highlights the benefits of getting exposure to it through biotech exchange traded funds (ETFs).
The number of publicly-traded U.S. biotech companies has diminished by 25% since 2007, writes Brett Chase [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/10/biotech-etfsbetter-way-play/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs: 5 Ways to Play Innovation</title>
		<link>http://www.etftrends.com/2010/08/biotech-etfs-5-ways-play-innovation/</link>
		<comments>http://www.etftrends.com/2010/08/biotech-etfs-5-ways-play-innovation/#comments</comments>
		<pubDate>Sun, 08 Aug 2010 20:00:05 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=34724</guid>
		<description><![CDATA[Biotechnology has been improving our quality of life for generations. The industry does everything from researching a cure for cancer to finding disease-resistant crops and more. While this can be a difficult sector in which to invest, there are five exchange traded funds (ETFs) that make it easier.
The biotech industry utilizes cellular and biomolecular processes [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/08/biotech-etfs-5-ways-play-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Feeling the Winds of Change</title>
		<link>http://www.etftrends.com/2010/07/biotech-etfs-feeling-winds-change/</link>
		<comments>http://www.etftrends.com/2010/07/biotech-etfs-feeling-winds-change/#comments</comments>
		<pubDate>Mon, 26 Jul 2010 18:00:14 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=34141</guid>
		<description><![CDATA[The biotechnology sector is about to see some major shifts as patents expire and M&#38;A activity gathers steam. Exchange traded funds (ETFs) are one of the best ways to get exposure to this dynamic and unpredictable sector.
Speculating on biotech mergers and acquisitions is about as solid a strategy as playing roulette, says John Jannarone for [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/07/biotech-etfs-feeling-winds-change/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

